Bispecific antibodies in NHL: current insights and ongoing studies

The promise of bispecific antibodies in the treatment of NHLПодробнее

Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHLПодробнее

The role of bispecific antibodies in the treatment landscape for R/R DLBCLПодробнее

Promising agents being explored in R/R MCL: bispecific antibodies and BTK inhibitorsПодробнее

Bispecific AntibodyПодробнее

Bispecific antibodies prior to alloSCT in NHL: a retrospective multi-center analysisПодробнее

How Bispecific Antibodies WorkПодробнее

Clinical guidance for the use of bispecific antibodies in NHLПодробнее

The role of bispecific antibodies in R/R NHL: the biology of these agents and what the future holdsПодробнее

Evolving Role of Bispecific Antibodies in B-cell Non-Hodgkin Lymphomas (B-NHL)Подробнее

Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Epcoritamab - Blood Cancers OncTalk 2023Подробнее

Bispecifics in NHL: epcoritamab and glofitamabПодробнее

Bispecific Antibodies in Lung Cancer - OncTalk Lung 2023Подробнее

Update on Bispecific Antibodies | Lymphoma Research Foundation WebinarsПодробнее

Understanding Bispecific AntibodiesПодробнее

How Bispecific Antibodies WorkПодробнее

How will bispecifics impact the treatment of NHL?Подробнее

Evolving Role of Bispecific Antibodies in B-cell Non-Hodgkin Lymphomas (B-NHL)Подробнее

Mechanistic model-informed discovery & development of bispecific antibodies for immuno-oncologyПодробнее